MIAMI BEACH, Fla. , July 26, 2024 /PRNewswire/ -- Immorta Bio Inc, a science-based longevity company dedicated to treating "Diseases of Aging and Aging as a DiseaseTM" with personalized cellular solutions, today announced the filing of an Investigational New Drug (IND) application with the Food and Drug Administration (FDA). The IND, which was granted #30745, is to initiate a clinical trial to evaluate safety, immunogenicity, and efficacy signals of SenoVax in patients with advanced non-small cell lung cancer.
The trial will recruit patients who have failed standard therapies and will comprise of three patient groups receiving increasing doses of SenoVax. SenoVax leverages dendritic cell technology to augment the natural ability of the immune system to clear senescent cells. These cells, referred to as "zombie cells", are known to accelerate the process of aging.
In the context of cancer, senescent cells have been demonstrated to surround tumors and to provide a protective element that "hides" cancers from immune attack 1,2,3,4 . Previous studies by Immorta Bio have shown that SenoVax can reduce growth of lung cancer in animal models and can induce immune responses that selectively kill senescent cells in the laboratory. "To our knowledge, this is the first clinical candidate to push the immune system to attack not the cancer itself, but the cells protecting it," said Thomas Ichim , PhD, President and Chief Scientific Officer of Immorta Bio.
"In contrast to cancer, which muta.